Clinical characteristics and prognostic significance of EBER positivity in diffuse large B-cell lymphoma: A meta-analysis

Xiaojuan Gao¹,2, Jia Li¹,2, Yaqi Wang¹,2, Shuai Liu¹,2,3, Baohong Yue¹,2,3,4,*

¹ Department of Laboratory Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China, ² Faculty of Laboratory Medicine, Zhengzhou University, Zhengzhou, P. R. China, ³ Key Laboratory of Henan Province, Faculty of Laboratory Medicine of Zhengzhou University, Zhengzhou, P. R. China, ⁴ Open Laboratory, Henan Province Key Subject of Clinical Medicine, Zhengzhou, P. R. China

* ybh2002@163.com

Abstract

Recent studies show that Epstein-Barr virus (EBV) positivity might be related to adverse prognosis in patients with diffuse large B-cell lymphoma (DLBCL), but the results are still inconclusive. We conducted this meta-analysis to define the clinical value of EBV infection in DLBCL. All potential articles in PubMed, Web of Science, Medline, and Embase were retrieved. Using the random-effects or fixed-effect model, pooled hazard ratios (HRs) or relative risk (RR) with 95% confidence intervals (CIs) were used to calculate the correlation between EBER and prognosis and clinical features in DLBCL. A total of 13 qualified studies with 4111 patients were identified in our meta-analysis based on the inclusion and exclusion criteria. The overall estimates revealed that EBV-encoded small RNAs (EBER) positivity was significantly correlated with worse overall survival (HR = 2.43, 95% CI: 1.73–3.36) and progression-free survival (HR = 3.60, 95% CI: 2.07–6.26). In addition, EBER positivity was associated with age older than 60 years (RR = 1.51, 95% CI: 1.02–2.24), male sex (RR = 1.34, 95% CI: 1.05–1.71), more advanced stage (RR = 2.25, 95% CI: 1.72–2.96), high international prognostic index (RR = 2.20, 95% CI: 1.71–2.82), more than one extranodal involvement (RR = 1.69, 95% CI: 1.27–2.26), presence of B symptom (RR = 1.75, 95% CI: 1.30–2.35), non-germinal center B-cell subtype (RR = 1.35, 95% CI: 1.03–1.78), and elevated lactate dehydrogenase levels (RR = 1.30, 95% CI: 0.98–1.72). EBER positivity was correlated with worse outcomes, worse clinical course, and adverse clinicopathologic features among patients with DLBCL.

Introduction

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for 30%–40% of all initially diagnosed cases [1]. It is an invasive lymphoma with heterogeneous histology, clinical features, surface marker expression, and clinical outcomes [2]. Only 50% of the patients with DLBCL achieve persistent remission.
The International Prognostic Index (IPI) is the most extensively used prognostic indicator in DLBCL [3]; it includes five clinical variables, namely, age, disease stage, performance status, serum lactate dehydrogenase (LDH) level, and the number of extranodal sites. However, the IPI score does not reflect the biological changes of tumor patients with DLBCL. Recently, the development of rituximab has transformed the chemotherapy regimen for aggressive lymphoma and led to remarkable progress in the outcome of DLBCL regardless of its IPI risk category [4]. In the rituximab era, the limitations of IPI score have become more prominent, and studies shown that the ability of IPI to identify risk groups has decreased [5]. In addition, considering the heterogeneous clinicopathological and genetic features of DLBCL, some reports suggested that although it is easy to implement, the IPI may not fully predict the prognosis of DLBCL [6–9]. Hence, identifying other valuable prognostic factors that can be used for the stratified treatment of DLBCL is crucial.

Epstein–Barr virus (EBV) infection is related to some lymphoid malignancies, such as Burkitt lymphoma, natural killer-cell leukemia/lymphoma, DLBCL, and a proportion of Hodgkin lymphoma cases, among others. Reports on the frequency of EBV-encoded small RNA (EBER)-positive DLBCL in different geographic regions have been substantially inconsistent, with the incidence being higher in Asian countries such as Japan and Korea (8%–9%) [10–12] than in some Western countries (1%–3%) [13, 14]. Many studies have focused on the prognostic value of EBV infection in DLBCL to determine potential prognostic markers and indicators for stratified treatment. However, the clinicopathological features and prognostic value of EBER positivity in patients with DLBCL remain controversial. Some studies showed that EBER positivity has an important prognostic value in DLBCL [10,11,15–20], whereas other studies reported opposite results [14,21–24]. Furthermore, determining prognostic factors at initial diagnosis may be helpful in providing risk-based stratification treatment for DLBCL and in identifying patients who need early intensive therapy. Thus, this meta-analysis was conducted to evaluate the prognostic value of EBER positivity in patients with DLBCL. Subgroup analyses was also conducted to further identify the association between EBER positivity and the clinical features of DLBCL. To the best of our knowledge, this is the first meta-analysis on such topic.

Methods

Search strategy

We conducted a systematic electronic search of PubMed, Embase, Medline, and Web of Science for potential articles published before February 31, 2018. We identified articles using the following corresponding keywords: “Epstein-Barr Virus,” “EB virus,” “EBV,” “human herpes-virus 4,” “HHV 4,” “diffuse large B cell lymphoma,” and “DLBCL.” No region limitation was adopted. Moreover, we manually checked the relevant studies to prevent omission of any research. We contacted authors and asked for additional information if the key data relevant to this meta-analysis were insufficient.

Selection criteria and quality assessment

Studies were selected if they met the following inclusion criteria: (1) confirmed histopathological diagnosis of DLBCL cases; (2) the prognostic value of EBER positivity among patients with DLBCL was estimated; (3) sufficient survival data to calculate the hazard ratio (HR) with 95% confidence interval (CI) were provided; (4) EBER was detected via in-situ hybridization; (5) more than 30 patients were enrolled in each study. When the same patient population was described in several reports, only the most informative one was included. Case reports, editorials, reviews, letters, conference abstracts, comments, and studies published in languages other
than English were excluded. Each included study was independently evaluated by two investigators using the Newcastle Ottawa Scale [25]. Moderate- to high-quality studies were defined as those with NOS scores of more than six points.

**Data extraction**

Two investigators independently extracted data from qualified articles. Disagreements were settled by consulting with a third reviewer. Clinical characteristics and prognosis data were extracted from the included studies. Information collected from each eligible study included the first author’s name, study location, publication year, number of patients, sex, median follow-up, thresholds, EBV status, and outcome correlation. We selected overall survival (OS) and progression free survival (PFS) as endpoints in this meta-analysis. The HR and its 95% CI were directly extracted from the original study or indirectly estimated from the Kaplan-Meier curves using software designed by Tierney et al. [26].

**Statistical analysis**

The pooled HR and the corresponding 95% CIs for OS and PFS were estimated using the random-effect model. An HR >1 indicated an unfavorable prognosis in EBER-positive DLBCL patients. In the analysis of the correlation between EBER positivity and clinicopathologic features (age, sex, disease stage, number of extranodal sites, serum LDH level, B symptom, histologic subtype, and IPI score), the relative risk (RR) was estimated via the fixed-effect model. An RR >1 suggested that EBER positivity was correlated to the parameter. Cochran’s Q test was used to assess the heterogeneity across studies, and \( P < 0.10 \) or \( I^2 \) statistic >50% was deemed to be statistically significant. The fixed-effects model was applied for \( P > 0.10 \) or \( I^2 < 50\% \); otherwise, the random-effects model was applied. We performed a sensitivity analysis by sequentially omitting each study to verify the stability of the results. Subgroup analyses were also performed based on the geographical setting of the study, which might be a potential source of heterogeneity. Begg’s and Egger’s tests were conducted to investigate potential publication bias. All statistical analyses were performed using Stata Version 12.0. \( P < 0.05 \) was considered statistically significant.

**Results**

**Selection and characteristics of the studies**

The search strategy is shown in Fig 1. A total of 1327 studies were retrieved for detailed screening. Of these, 1279 studies were excluded due to duplication (n = 425) and irrelevance or them being another type of study other than research (n = 854). The full text of the 48 potentially qualified articles were reviewed. Finally, after excluding those with non-survival analysis data or those whose HR was not obtained, 13 articles [10,11,14–24] were included in the meta-analysis.

The baseline features of the 13 eligible studies are presented in Table 1. A total of 4111 participants (ranging from 74 to 703 for each article) were included in this meta-analysis. The incidence of EBER positivity in these studies ranged from 1.4% to 14.9%. Ten studies were from Asian countries [10,11,15–20,22,24], two from Caucasian countries [14,23], and one from Peru [21]. The HRs with 95% CIs were directly extracted in 9 original studies [11,14,15,18–20,22–24]. Four studies [10,16,17,21] indirectly calculated these values from Kaplan-Meier curves proposed by Tierney et al. [26]. In terms of methodological quality, all included studies scored more than six points on the NOS, indicating a relative high quality.
Overall analyses

Data on the HRs for the correlation between EBER positivity and OS were available in all 13 studies [10,11,14–24], while those for PFS were available in 5 studies [10,14,16–18]. The overall estimate demonstrated that EBER positivity in DLBCL was correlated with unfavorable outcome for OS (HR = 2.43, 95% CI: 1.73–3.36, \(P<0.001\)).
The heterogeneity is moderate ($I^2 = 61.1\%, P = 0.002$) among these studies; therefore, a random-effects model was adopted to elevate the pooled HR. The pooled HR on PFS was 3.60 (95% CI, 2.07–6.26, $P < 0.001$) as calculated via random-effects model for the existence of a considerable heterogeneity ($I^2 = 73.4\%, P = 0.005$) (Fig 2). This result showed a distinctly increased risk of disease progression in the EBER-positive DLBCL group.

**Subgroup analyses**

To explain the heterogeneity, we conducted a subgroup analysis by geographical location using a random-effects model. In the analysis of OS, we divided the patients into different geographical groups as follows: Korea, Japan, China, USA, Taiwan, and Peru (Fig 3). Worse prognosis was strongly correlated to EBER positivity in Korea (n = 3 studies, HR = 2.84, 95% CI: 1.96–4.10, $I^2 = 24.8\%$), Japan (n = 2 studies, HR = 5.16, 95% CI: 2.40–11.06, $I^2 = 0.0\%$), Peru (n = 1 study, HR = 3.10, 95% CI: 1.18–8.15), and China (n = 2 studies, HR = 3.46, 95% CI: 1.28–9.32, $I^2 = 81.8\%$). By contrast, there was no significant difference in Taiwan (n = 3 studies, HR = 1.34, 95% CI: 0.81–2.22, $I^2 = 0.0\%$) and USA (n = 2 studies, HR = 1.17, 95% CI: 0.64–2.13, $I^2 = 5.5\%$).

**Correlation between EBER positivity and clinical features**

Ten studies had information on the correlation between EBER positivity and age in DLBCL. A meta-analysis of five studies [10,11,14,19,21] showed an association between EBER positivity and age >60 years (RR = 1.51, 95% CI: 1.02–2.24). The heterogeneity across these studies was moderate ($I^2 = 43.2\%, P = 0.134$). However, a meta-analysis of four studies [15,16,20,23] suggested that EBER positivity was not significantly correlated to age >50 years (RR = 1.26, 95% CI: 0.87–1.84). No considerable heterogeneity was noted across these studies ($I^2 = 18.8\%, P = 0.296$) (Fig 4A). An analysis of twelve studies [10,11,14–17,19–24] revealed that EBER positivity was more prevalent in men (RR = 1.34, 95% CI: 1.05–1.71). No heterogeneity was noted across these studies ($I^2 = 0.0\%, P = 0.596$) (Fig 4B). An analysis of ten studies [10,11,14,16,17,19–21,23,24] revealed that EBER positivity was correlated with more advanced
disease stage (I+II vs III+IV, RR = 2.25, 95% CI: 1.72–2.96). No heterogeneity was noted across these studies ($I^2 = 0.0\%$, $P = 0.440$) (Fig 4C). An analysis of eleven studies [10,11,14–17,19–21,23,24] indicated that EBER positivity was associated with higher international IPI score (1–2 vs 3–4, RR = 2.20, 95% CI: 1.71–2.82). The heterogeneity across these studies was moderate ($I^2 = 26.2\%$, $P = 0.194$) (Fig 4D). An analysis of ten studies [10,11,14,15,17,19–21,23,24] indicated that EBER positivity was associated with more than one extranodal involvement (RR = 1.69, 95% CI: 1.27–2.26). The heterogeneity across these studies was moderate ($I^2 = 20.6\%$, $P = 0.253$) (Fig 5A). An analysis of seven studies [10,11,14,15,17,20,24] indicated that EBER positivity was associated with the presence of B symptom (RR = 1.69, 95% CI: 1.27–2.26). The heterogeneity across these studies was moderate ($I^2 = 20.6\%$, $P = 0.253$) (Fig 5A). An analysis of eleven studies [10,11,14–16,19–24] indicated that EBER positivity was associated with non-germinai center B-cell (GCB) subtype (RR = 1.35, 95% CI: 1.03–1.78). The heterogeneity across these studies was moderate ($I^2 = 30.6\%$, $P = 0.155$) (Fig 5C). An analysis of ten studies [10,11,14–17,19,21,23,24] indicated that EBER positivity tended to be associated with elevated LDH levels (RR = 1.30, 95% CI: 0.98–1.72). No heterogeneity was noted across these studies ($I^2 = 0.0\%$, $P = 0.600$) (Fig 5D).

---

**Fig 2.** Forest plot of the hazard rations for progression free survival (PFS) between patients with EBER-positive and EBER-negative DLBCL.

https://doi.org/10.1371/journal.pone.0199398.g002

---

| Study                        | HR (95% CI) | Weight |
|------------------------------|-------------|--------|
| Hong JY (2017)               | 3.40 (1.68, 6.90) | 19.49  |
| Ok CY (2014)                 | 1.48 (0.64, 3.41) | 17.32  |
| Okamoto A (2015)             | 7.26 (2.76, 19.09) | 15.26  |
| Park S (2007)                | 2.54 (1.61, 4.01) | 23.96  |
| Lu TX (2015)                 | 6.50 (4.12, 10.26) | 23.97  |
| Overall (I–squared = 73.4\%, p = 0.005) | 3.60 (2.07, 6.26) | 100.00 |

**NOTE:** Weights are from random effects analysis.
To evaluate the stability of results, we conducted a sensitivity analysis by excluding each eligible study. The results showed that no individual study substantially influenced the pooled HR for OS (S1 Fig). Begg’s and Egger’s tests for estimating publication bias for OS in this meta-analysis showed no substantial publication bias (Begg’s test, \( P = 1 \) (S2 Fig); Egger’s test, \( P = 0.476 \) (S3 Fig)).
Discussion

Although many studies demonstrated that EBER positivity indicated worse clinical features and poor prognosis in DLBCL patients, there is still no unified conclusion. Therefore, we conducted the first meta-analysis of published literature to systemically explore the prognostic value of EBV positivity in DLBCL. Our results demonstrated that EBER positivity significantly
predicted poor PFS and short OS (increased risk of tumor relapse and death). Moreover, subgroup analysis showed that EBER positivity is related to inferior clinicopathological parameters and aggressive clinical course in DLBCL patients. Thus, EBER positivity should be considered as a valuable prognostic marker and risk-stratifying factor in DLBCL.

**Fig 5.** Meta-analysis of the association between EBER positivity and clinical features in DLBCL patients. (A) Number of extranodal involvement (>1 vs ≤1); (B) B symptom (presence vs absence); (C) immunohistochemical profile (non-GCB vs GCB); (D) LDH levels (elevated vs normal).

https://doi.org/10.1371/journal.pone.0199398.g005
Consistent with other findings, our results revealed that patients with EBER-positive DLBCL tended to be men, aged >60 years, who had higher IPI scores, a non-GCB immunophenotype, more than one extranodal site, an advanced disease stage, B symptom, and elevated LDH levels. These clinical features correspond to the invasive clinical course of DLBCL. Subgroup analysis might reveal the reason by which EBER positivity was associated with poor OS and PFS among patients with DLBCL. Several studies strongly suggest that EBV-associated viral proteins play an important role in oncogenesis, including regulation of proliferation, metastasis, immune escape, and cell apoptosis [27–29]. Latent membrane protein 1 (LMP1), an important oncogenic protein encoded by EBV, stimulate proliferation of B cells via activate nuclear factor-kappa B (NFkB) and transcription factor AP-1 [30]. LMP1 can also inhibit the apoptosis of tumor cells by inducing the expression of anti-apoptotic genes A20 and Bcl-2 [31]. Epstein-Barr nuclear antigen 1 (EBNA1) can restrict the translation of its own mRNA through a specific region and suppress antigenic peptides combined with major histocompatibility complex I (MHC-1) [32], which can cause virus-carrying host cells to evade the identification of cytotoxic T lymphocytes (CTL), thus avoiding the apoptotic action of the immune system. Moreover, EBNA1 can prevent the degradation of lytic enzymes and the activation of CTL [33]. When the normal immune function is compromised, malignant neoplasms develop easier. Collectively, these mechanisms can explain the association between EBER positivity and unfavorable clinicopathological parameters in DLBCL patients. Thus, EBER positivity can be a reliable marker for predicting the prognosis of DLBCL, compensating for the deficiency in the current prognostic scoring system.

However, our meta-analysis has several limitations. First, a certain degree of heterogeneity existed among the studies for the overall meta-analysis. We investigated the potential sources of the heterogeneity using subgroup analysis and found that most of the heterogeneity was derived from the different regions of the studies. In this subgroup analysis, a significant correlation of EBER positivity with OS was noted in Korea, Japan, China, and Peru. By contrast, there was no significant correlation in Taiwan and the USA, which might be related to differences in race and lifestyle. Interestingly, the frequency of EBV-positive DLBCL was higher in Korea (6.7%–8.9%) [10,18,20], Japan (5.9%–8.2%) [11,17], China (10.3%–14%) [15,16], and Peru (14.9%) [19] than in Taiwan (1.7%–5.7%) [21,22,24] and the USA (4.0%–4.4%) [14,23]. The elderly may develop immunodeficiency-associated lymphoproliferative disorders through senescence of the immune system as part of the normal aging process. This leads to low-grade chronic infections such as EBV infection [14]. Thus, the age distribution and the ageing index (ratio of the number of people aged ≥65 years to the number of those aged ≤15 years) might be related to the different incidence of EBV, resulting in a diverse risk of DLBCL in different geographic regions. In addition, although laboratory tests should not be the major source of variation because we only included studies that evaluated EBER via in-situ hybridization of paraffin-embedded tissue, subtle differences in technical quality cannot be eliminated. EBER detection via in-situ hybridization is considered the gold standard for evaluating EBER positivity, but this method is a semi-quantitative analysis, and, to a certain degree, the reported results depend on the observer [17]. Other unidentified factors may have played a role in the heterogeneity of the current meta-analysis. Second, there is no established standard for the proportion of EBV-positive cells in EBV-positive DLBCL, which is a limitation when evaluating disease prevalence [13]. Some studies reported that the different cut-off values for EBER-positive cells are bound to influence the prevalence of EBV-positive DLBCL [34,35]. As shown in Table 1, the criteria for defining EBV-positive cases varied among the included studies and ranged from 10% to 50%, while it was not defined in one study [19]. Specifically, a study from China adopting the two most commonly used cut-off values of >20% and >50% reported EBV-positive rates of 14% and 10.4%, respectively [16]. However, this study showed that EBER-positive patients harbored inferior
prognosis and aggressive clinical course compared with EBER-negative patients irrespective of the cut-off values of EBER positivity. Even so, a unified cut-off value for EBV positivity still need to be established and should either be >20%, >30%, or 100%. Third, some HRs with 95% CI calculated from the survival curves might be less reliable than those directly extracted from the original study. Finally, we have included all available data, but we only found most published studies from Asia, especially the lack of Europe data. This emphasises the need for future studies to test the association of EBV infection with prognosis in DLBCL in the Western countries, generally lower prevalence of EBER-positive DLBCL.

In conclusion, the results of the meta-analysis revealed that EBER positivity in patients with DLBCL is associated with worse clinical course and poor survival. EBER positivity tended to be correlated with male sex, age older than 60 years, high IPI score, more advanced staged, more than one extranodal involvement, the presence of B symptom, non-GCB subtype, and elevated LDH levels. EBER positivity might be a useful predictive indicator of poor outcome and can be used in determining appropriate individualized treatment modality for patients with DLBCL. More high-quality and larger prospective clinical studies with a standard cut-off value for EBV positivity are essential to accurately define the role of EBV in the prognosis of DLBCL.

Supporting information

S1 File. PRISMA checklist.
(DOC)

S2 File. Search strategy of this study.
(DOCX)

S1 Fig. Sensitivity analysis for the pooled HRs in OS.
(TIF)

S2 Fig. Begg’s funnel plots of the prognostic role of EBER positivity in OS.
(TIF)

S3 Fig. Egger’s linear regression test of the prognostic role of EBER positivity in OS.
(TIF)

Author Contributions

Conceptualization: Xiaojuan Gao, Jia Li, Yaqi Wang, Baohong Yue.

Data curation: Xiaojuan Gao.

Formal analysis: Xiaojuan Gao.

Investigation: Jia Li.

Methodology: Xiaojuan Gao, Jia Li, Yaqi Wang.

Project administration: Baohong Yue.

Software: Xiaojuan Gao.

Supervision: Shuai Liu, Baohong Yue.

Validation: Shuai Liu, Baohong Yue.

Writing – original draft: Xiaojuan Gao.

Writing – review & editing: Xiaojuan Gao, Jia Li, Yaqi Wang.
References

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997; 89: 3909–3918. PMID: 9166827

2. Rossi D, Gaidano G. Molecular heterogeneity of diffuse large B-cell lymphoma: implications for disease management and prognosis. Hematology. 2002; 7: 239–252. https://doi.org/10.1080/102453302000024058 PMID: 14972786

3. Nakayama S, Yokote T, Hirata Y, Akikawa T, Miyoshi T, Hiraoka N, et al. TNF-alpha expression in tumor cells as a novel prognostic marker for diffuse large B-cell lymphoma, not otherwise specified. Am J Surg Pathol. 2014; 38: 228–234. https://doi.org/10.1097/PAS.0000000000000094 PMID: 24145654

4. Kubuscho B, Held G, Pfreundschuh M. Management of diffuse large B-cell lymphoma (DLBCL). Cancer Treat Res. 2015; 165: 271–288. https://doi.org/10.1007/978-3-319-13150-4_11 PMID: 25655614

5. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28: 2373–2380. https://doi.org/10.1200/JCO.2009.26.2493 PMID: 20385988

6. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007; 109: 1857–1861. https://doi.org/10.1182/blood-2006-08-038257 PMID: 17105812

7. Baris A, Marcheselli L, Sacchi S, Marcheselli R, Pozzi S, Ferri P, et al. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol. 2010; 21: 1486–1491. https://doi.org/10.1093/annonc/mdp531 PMID: 19920060

8. Czuczaman MS, Grillo-Lopez AJ, Alkuzuweny B, Weaver R, Larocca A, McLaughlin P. Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab. Leuk Lymphoma. 2006; 47: 1830–1840. https://doi.org/10.1080/10428190600709523 PMID: 17064996

9. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Berry B, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007; 109: 1857–1861. https://doi.org/10.1182/blood-2006-08-038257 PMID: 17064996

10. Hong JY, Ko YH, Kim SJ, Kim WS. Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly: a concise review and update. Curr Opin Oncol. 2015; 27: 392–398. https://doi.org/10.1097/CCO.0000000000000210 PMID: 26258272

11. Sato A, Nakamura N, Kojima M, Ohmachi K, Esteban JC, Kikuti YY, et al. The clinical outcome of Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly in the rituximab era. Cancer Sci. 2014; 105: 1170–1175. https://doi.org/10.1111/cas.12467 PMID: 24974976

12. Hong JY, Ko YH, Kim SJ, Kim WS. Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly: a concise review and update. Curr Opin Oncol. 2015; 27: 392–398. https://doi.org/10.1097/CCO.0000000000000210 PMID: 26258272

13. Ok CY, Papathomas TG, Medeiros LJ, Young KH. EBV-positive diffuse large B-cell lymphoma of the elderly. Blood. 2013; 122: 328–340. https://doi.org/10.1182/blood-2013-03-489708 PMID: 23649469

14. Ok CY, Li L, Xu-Monette ZY, Visco C, Tzankov A, Manyam GC, et al. Prevalence and clinical implications of Epstein-Barr virus infection in de novo diffuse large B-cell lymphoma in Western Countries. Clin Cancer Res. 2014; 20: 2338–2349.

15. Liang JH, Lu TX, Tian T, Wang L, Fan L, Xu J, et al. Epstein-Barr virus (EBV) DNA in whole blood as a superior prognostic and monitoring factor than EBV-encoded small RNA in situ hybridization in diffuse large B-cell lymphoma. Clin Microbiol Infect. 2015; 21: 596–602. https://doi.org/10.1016/j.cmi.2015.02.017 PMID: 25743579

16. Lu TX, Liang JH, Miao Y, Fan L, Wang L, Qu XY, et al. Epstein-barr virus-positive diffuse large b-cell lymphoma predict poor outcome, regardless of the age. Sci Rep. 2015; 5: 12168. https://doi.org/10.1038/srep12168 PMID: 26202875

17. Okamoto A, Yanada M, Inaguma Y, Tokuda M, Morishima S, Kanie T, et al. The prognostic significance of EBV DNA load and EBER status in diagnostic specimens from diffuse large B-cell lymphoma patients. Hematol Oncol. 2015; 35: 87–93. https://doi.org/10.1002/hon.2245 PMID: 26177728

18. Hong JY, Ryu KJ, Park C, Hong M, Ko YH, Kim WS, et al. Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Oncotarget. 2017; 8: 13782–13791. https://doi.org/10.18632/oncotarget.14636 PMID: 28099151
19. Morales D, Beltran B, De Mendoza FH, Riva L, Yabar A, Quiñones P, et al. Epstein-Barr virus as a prognostic factor in de novo nodal diffuse large B-cell lymphoma. Leuk Lymphoma. 2010; 51: 66–72. https://doi.org/10.3109/10428190903308015 PMID: 19860616

20. Hong JY, Yoon DH, Suh C, Huh J, Do IG, Sohn I, et al. EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity? Ann Oncol. 2015; 26: 548–555. https://doi.org/10.1093/annonc/mdu556 PMID: 25475080

21. Lu CH, Lee KF, Chen CC, Chen YY, Huang CE, Tsai PS, et al. Clinical Characteristics and Treatment Outcome in a Taiwanese Population of Patients with Epstein–Barr Virus-positive Diffuse Large B-cell Lymphoma. Jpn J Clin Oncol. 2014; 44: 1164–1171. https://doi.org/10.1093/jjco/hyu155 PMID: 25320341

22. Chang ST, Lu YH, Lu CL, Weng SF, Lin SH, Kuo SY, et al. Epstein–Barr virus is rarely associated with diffuse large B cell lymphoma in Taiwan and carries a trend for a shorter median survival time. J Clin Pathol. 2014; 67: 326–332. https://doi.org/10.1136/jclinpath-2013-201905 PMID: 24218026

23. Tracy S, Habermann TM, Feldman AL, Maurer MJ, Dogan A, Perepu US, et al. Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. Haematologica. 2018; 103: 297–303. https://doi.org/10.3324/haematol.2017.176511 PMID: 29170255

24. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25: 603–605. https://doi.org/10.1007/s10654-010-9491-z PMID: 20652370

25. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8: 16. https://doi.org/10.1186/1745-6215-8-16 PMID: 17555582

26. Mesri Enrique A, Feitelson MA, Munger K. Human Viral Oncogenes is: A Cancer Hallmarks Analysis. Cell Host Microbe. 2014; 15: 266–282. https://doi.org/10.1016/j.chom.2014.02.011 PMID: 24629334

27. Gruhne B, Sompallae R, Masucci MG. Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints. Oncogene. 2009; 28: 3997–4008. https://doi.org/10.1038/onc.2009.258 PMID: 19718051

28. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol. 2001; 1: 75–82. https://doi.org/10.1038/3509584 PMID: 11905817

29. Kilger E, Kieser A, Baumann M, Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J. 1998; 17: 1700–1709. https://doi.org/10.1093/embj/17.7.1700 PMID: 9501091

30. Kleines M, Finke K, Ritter K, Schaade L. Induction of growth rate and transcriptional modulation of growth promoters and growth inhibitors in epithelial cells by EBV-LMP1. Virus Res. 2000; 68: 63–69. PMID: 10930663

31. Daskalogiannii C, Pyndiah S, Apcher S, Mazars A, Manoury B, Ammari N, et al. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers. J Pathol. 2015; 235: 334–341. https://doi.org/10.1002/path.4431 PMID: 25186125

32. Jones RJ, Smith LJ, Dawson CW, Haigh T, Blake NW, Young LS. Epstein-Barr virus nuclear antigen 1 (EBNA1) induced cytoxicity in epithelial cells is associated with EBNA1 degradation and processing. Virology. 2003; 313: 663–676. PMID: 12954232

33. Chuang SS, Ichinohasama R, Yang CC, Wang WC, Chou CK, Liao YL, et al. Multicentric primary intestinal EBV-positive diffuse large B cell lymphoma of the elderly presenting with perforation. Int J Hematol. 2010; 91: 534–538. https://doi.org/10.1007/s12185-010-0512-1 PMID: 20155338

34. Wada N, Ikeda J, Hori Y, Fujita S, Ogawa H, Soma T, et al. Epstein-barr virus in diffuse large B-Cell lymphoma in immunocompetent patients in Japan is as low as in Western Countries. J Med Virol. 2011; 83: 317–321. https://doi.org/10.1002/jmv.21967 PMID: 21181929